Trial · NCT02637999
Adverse events51
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 51
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Leucopenia | Blood and lymphatic system disorders | MXB Then PEG IFN | 7 | 8 | 16 |
| other | Leucopenia | Blood and lymphatic system disorders | MXB + PEG IFN Then PEG IFN | 7 | 8 | 11 |
| other | Leucopenia | Blood and lymphatic system disorders | PEG IFN | 7 | 8 | 17 |
| other | Neutropenia | Blood and lymphatic system disorders | MXB Then PEG IFN | 7 | 8 | 17 |
| other | Neutropenia | Blood and lymphatic system disorders | MXB + PEG IFN Then PEG IFN | 7 | 8 | 15 |
| other | Neutropenia | Blood and lymphatic system disorders | PEG IFN | 7 | 8 | 21 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | MXB Then PEG IFN | 6 | 8 | 21 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | MXB + PEG IFN Then PEG IFN | 5 | 8 | 14 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | PEG IFN | 6 | 8 | 20 |
| other | Anaemia | Blood and lymphatic system disorders | MXB Then PEG IFN | 2 | 8 | 2 |
| other | Anaemia | Blood and lymphatic system disorders | MXB + PEG IFN Then PEG IFN | 0 | 8 | 0 |
| other | Anaemia | Blood and lymphatic system disorders | PEG IFN | 0 | 8 | 0 |
| other | Eosinophilia | Blood and lymphatic system disorders | MXB Then PEG IFN | 1 | 8 | 1 |
| other | Eosinophilia | Blood and lymphatic system disorders | MXB + PEG IFN Then PEG IFN | 0 | 8 | 0 |
| other | Eosinophilia | Blood and lymphatic system disorders | PEG IFN | 0 | 8 | 0 |
| other | Alanine aminotransferase increased | Investigations | MXB Then PEG IFN | 7 | 8 | 11 |
| other | Alanine aminotransferase increased | Investigations | MXB + PEG IFN Then PEG IFN | 3 | 8 | 4 |
| other | Alanine aminotransferase increased | Investigations | PEG IFN | 3 | 8 | 6 |
| other | Aspartate aminotransferase increased | Investigations | MXB Then PEG IFN | 6 | 8 | 6 |
| other | Aspartate aminotransferase increased | Investigations | MXB + PEG IFN Then PEG IFN | 3 | 8 | 5 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02637999/events